This is a preview of subscription content, log in via an institution to check access.
Notes
Three times gross domestic product per capita in China.
Reference
Chen P, et al. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. Clinical Drug Investigation : 7 Sep 2018. Available from: URL: http://doi.org/10.1007/s40261-018-0702-9
Rights and permissions
About this article
Cite this article
Elbasvir/grazoprevir dominates for chronic HCV in China. PharmacoEcon Outcomes News 813, 10 (2018). https://doi.org/10.1007/s40274-018-5317-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5317-0